1-benzo[d][1,3]dioxol-5-yloxy-3-[4-(2-pyrimidinyl)hexahydro-1-pyrazinyl]propane | 790162-31-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-benzo[d][1,3]dioxol-5-yloxy-3-[4-(2-pyrimidinyl)hexahydro-1-pyrazinyl]propane
• 英文别名: 2-[4-[3-(1,3-Benzodioxol-5-yloxy)propyl]piperazin-1-yl]pyrimidine
• CAS: 790162-31-1
• 化学式: C₁₈H₂₂N₄O₃
• 分子量: 342.398
• InChiKey: CJSLMANLNGOVCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  60
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Use of Adrenergic N-Phenylpiperazine Antagonists, Pahrmaceutical Compositions Containning Them, and Methods of Preparing Them
  申请人：Soares Romeiro Antonio Luiz

  公开号：US20070219213A1

  公开（公告）日：2007-09-20

  The present invention describes phenylpiperazinyl alpha adrenergic antagonists that corresponds to the formula (I) which selectively act on the alpha 1A/alpha 1D subtypes, where its selectivity index in comparison to alpha 1B subtype is, at minimum, 1700 for the alpha 1A subtype and 10000 for the alpha 1 D subtype, being therefore useful for the treatment of the lower urinary tract symptoms, including the benign prostatic hyperplasia treatment in mammals, preferentially humans. It is also described pharmaceutical compositions containing said compounds and methods for its preparation.

  本发明描述了与公式（I）相对应的苯基哌嗪基α肾上腺素受体拮抗剂，其选择性作用于α1A/α1D亚型，其中与α1B亚型相比的选择性指数，对于α1A亚型至少为1700，对于α1D亚型至少为10000，因此可用于治疗哺乳动物，尤其是人类的下尿路症状，包括良性前列腺增生的治疗。还描述了含有该化合物的药物组合物以及其制备方法。
• USE OF ADRENERGIC N-PHENYLPIPERAZINE ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHODS OF PREPARING THEM
  申请人：Soares Romeiro Luiz Antonio

  公开号：US20120232094A1

  公开（公告）日：2012-09-13

  The present invention describes phenylpiperazinyl alpha adrenergic antagonists that corresponds to the formula (I) which selectively act on the alpha 1A/alpha 1D subtypes, where its selectivity index in comparison to alpha 1B subtype is, at minimum, 1700 for the alpha 1A subtype and 10000 for the alpha 1D subtype, being therefore useful for the treatment of the lower urinary tract symptoms, including the benign prostatic hyperplasia treatment in mammals, preferentially humans. Also described are pharmaceutical compositions containing said compounds and methods for its preparation.